Trevi Therapeutics, Inc. (TRVI)

NASDAQ: TRVI · IEX Real-Time Price · USD
1.11
-0.01 (-1.33%)
At close: Dec 1, 2023, 4:00 PM
1.10
-0.01 (-0.54%)
After-hours: Dec 1, 2023, 5:48 PM EST
-1.33%
Market Cap 70.88M
Revenue (ttm) n/a
Net Income (ttm) -26.75M
Shares Out 63.86M
EPS (ttm) -0.22
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 404,392
Open 1.11
Previous Close 1.13
Day's Range 1.10 - 1.15
52-Week Range 0.97 - 3.50
Beta 0.80
Analysts Strong Buy
Price Target 6.75 (+508.11%)
Earnings Date Nov 9, 2023

About TRVI

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio for the treatment of serious cough conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b/3 clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize product... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date May 7, 2019
Employees 25
Stock Exchange NASDAQ
Ticker Symbol TRVI
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for TRVI stock is "Strong Buy." The 12-month stock price forecast is $6.75, which is an increase of 508.11% from the latest price.

Price Target
$6.75
(508.11% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Trevi Therapeutics Announces Third Quarter 2023 Financial Results and Provides Business Update

Initiated Phase 2a RIVER trial of Haduvio in refractory chronic cough (RCC) patients and expect topline data in the second half of 2024 Expect to initiate Phase 2b dose-ranging trial of Haduvio for th...

24 days ago - PRNewsWire

Trevi Therapeutics Announces the Initiation of its Phase 2a RIVER Clinical Trial of Haduvio™ for Refractory Chronic Cough

Expect to enroll 60 subjects across a broad range of cough frequencies RIVER topline data expected in the second half of 2024 NEW HAVEN, Conn. , Nov. 2, 2023 /PRNewswire/ -- Trevi Therapeutics, Inc. (...

4 weeks ago - PRNewsWire

Trevi Therapeutics to Report Q3 2023 Financial Results and Provide a Corporate Update on November 9, 2023

Conference call and webcast to be held at 4:30 p.m. EDT NEW HAVEN, Conn.

4 weeks ago - PRNewsWire

Trevi Therapeutics Announces Results from Phase 2b/3 PRISM Open-Label Extension Study of Haduvio™ in Prurigo Nodularis

Continued reduction in WI-NRS observed among participants who remained in the study through 52 weeks of treatment Safety data over 52 weeks: treatment was well tolerated and consistent with 14-week bl...

7 weeks ago - PRNewsWire

Trevi Therapeutics to Participate in Upcoming September Events

NEW HAVEN, Conn. , Sept. 6, 2023 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER...

3 months ago - PRNewsWire

Trevi Therapeutics Announces Second Quarter 2023 Financial Results and Provides Business Update

Plans to initiate three clinical studies in chronic cough indications for later this year remain on track Data from Phase 2 CANAL trial of chronic cough in patients with idiopathic pulmonary fibrosis ...

4 months ago - PRNewsWire

Trevi Therapeutics to Report Q2 2023 Financial Results and Provide a Corporate Update on August 10, 2023

Conference call and webcast to be held at 4:30 p.m. EDT NEW HAVEN, Conn.

4 months ago - PRNewsWire

Trevi Therapeutics to Participate in Upcoming August Events

NEW HAVEN, Conn. , Aug. 1, 2023 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER)...

4 months ago - PRNewsWire

Trevi Therapeutics to Participate in Upcoming July Investor Events

NEW HAVEN, Conn. , July 6, 2023 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER)...

5 months ago - PRNewsWire

Trevi Therapeutics to Participate in Upcoming June Conferences

Dr. Toby Maher will be presenting data results from the Phase 2 CANAL trial in IPF chronic cough at American Cough Conference NEW HAVEN, Conn. , May 30, 2023 /PRNewswire/ -- Trevi Therapeutics, Inc. (...

6 months ago - PRNewsWire

Trevi Therapeutics Announces Publication of Positive Data from the CANAL Trial in IPF Chronic Cough in NEJM Evidence

Nalbuphine ER resulted in a rapid and marked reduction in recorded daytime cough among patients suffering from IPF-related cough The mean change in 24-hour objective cough frequency was similar in pat...

6 months ago - PRNewsWire

Trevi Therapeutics Announces First Quarter 2023 Financial Results and Provides Business Update

I nitiating three clinical studies in chronic cough indications later this year Received Notice of Allowance for key U.S. patent for the use of oral nalbuphine ER for the treatment of chronic cough in...

7 months ago - PRNewsWire

Trevi Therapeutics to Present at Upcoming Yale Innovation Summit 2023

Presentation to take place on June 1 from 10:30 a.m. to 12:00 p.m.

7 months ago - PRNewsWire

Trevi Therapeutics to Report Q1 2023 Financial Results and Provide a Corporate Update on May 11, 2023

Conference call and webcast to be held at 4:30 p.m. EDT NEW HAVEN, Conn.

7 months ago - PRNewsWire

Trevi Therapeutics Announces Two Presentations on the Phase 2 CANAL Data at the ATS 2023 International Conference

Dr. Toby Maher of the Keck School of Medicine will give oral presentations for both scientific abstracts on oral nalbuphine extended release for chronic cough in IPF NEW HAVEN, Conn. , May 2, 2023 /PR...

7 months ago - PRNewsWire

Trevi Therapeutics to Participate in Upcoming May Investor Events

2023 Aegis Virtual Conference, May 2-4 American Thoracic Society's (ATS) 2023 Respiratory Innovation Summit (RIS), May 19-20 Yale Innovation Summit, May 31-June 1 NEW HAVEN, Conn. , April 27, 2023 /PR...

7 months ago - PRNewsWire

Trevi Therapeutics to Participate in the 22nd Annual Needham Virtual Healthcare Conference

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in adults wi...

8 months ago - PRNewsWire

Trevi Therapeutics Announces Fourth Quarter and Year End 2022 Financial Results and Provides Business Update

Multiple trial initiations planned for 2023 to progress Haduvio in chronic cough indications Management to host a conference call and webcast today at 4:30 p.m. EDT NEW HAVEN, Conn.

9 months ago - PRNewsWire

Trevi Therapeutics to Report Q4 and Year End 2022 Financial Results and Provide a Corporate Update on March 16, 2023

Conference call and webcast to be held at 4:30 p.m. EDT NEW HAVEN, Conn.

9 months ago - PRNewsWire

Trevi Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering Use of Haduvio™ (nalbuphine ER) for the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis

NEW HAVEN, Conn. , March 8, 2023 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER...

9 months ago - PRNewsWire

Trevi Therapeutics to Participate in Upcoming March Conferences

Frazier/Fenwick Winter Investor Event, March 7-10 Oppenheimer 33rd Annual Healthcare Conference, March 13-15 – Corporate presentation will be held on Monday, March 13, at 4:00 p.m. ET BIO-Europe Sprin...

9 months ago - PRNewsWire

Trevi Therapeutics to Present at the Emerging Growth Conference on February 22, 2023

Corporate presentation at 10:50 a.m. ET NEW HAVEN, Conn.

10 months ago - PRNewsWire

Trevi Therapeutics to Present and Participate in Upcoming February Conferences

BIO CEO & Investor Conference, February 6-9 – Corporate presentation Tuesday, February 7, at 10:45 a.m. ET SVB Securities Global Biopharma Conference, February 13-16 – Corporate presentation Tuesday, ...

10 months ago - PRNewsWire

Trevi Therapeutics, Inc. Discusses Progress and 2022 Success of Clinical Studies for Its Investigational Oral Therapy Haduvio(TM) with The Stock Day Podcast

Phoenix, Arizona--(Newsfile Corp. - January 25, 2023) - The Stock Day Podcast welcomed Trevi Therapeutics, Inc. (NASDAQ: TRVI) ("the Company"), a clinical-stage biopharmaceutical company developing th...

11 months ago - Newsfile Corp

Trevi Therapeutics Provides Business Update Ahead of Upcoming Conferences

NEW HAVEN, Conn. , Jan. 5, 2023 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER)...

11 months ago - PRNewsWire